Hansa Biopharma AB (publ) (HNSBF)

2,9300 0,0000 (0,00%) Börsenschluss: 09:30AM EDT

Hansa Biopharma AB (publ)

ScheelevAegen 22
Lund 223 63
Sweden
46 46 16 56 70
https://www.hansabiopharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 168

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Søren Tulstrup M.Sc	President & CEO	16,12M	N/A	1965
Mr. C. Evan Ballantyne	Chief Financial Officer	N/A	N/A	1960
Dr. Christian Kjellman	Senior VP & COO	N/A	N/A	1967
Dr. Hitto Kaufmann Ph.D.	Chief Scientific Officer	N/A	N/A	1971
Ms. Eva-Maria Joed	Vice President of Finance & Administration	N/A	N/A	1969
Mr. Klaus Sindahl	VP & Head of Investor Relations	N/A	N/A	N/A
Ms. Anne Säfström Lanner	Senior VP & Chief Human Resources Officer	N/A	N/A	1969
Mr. Emanuel Björne	VP & Head of Business Development	N/A	N/A	1973
Dr. Lena Winstedt	Head of Science	N/A	N/A	1969
Ms. Vincenza Nigro M.B.A.	VP & Head of Medical Affairs	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Corporate Governance

Hansa Biopharma AB (publ)s ISS Governance QualityScore, Stand 1. April 2024, lautet 1. Die grundlegenden Scores sind Audit: 8, Vorstand: 2, Shareholderrechte: 1, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.